Abstract:
Objective To retrospectively investigate the efficiency of Jinlong capsule combined with transarterial chemoembolization for the treatment of advanced pancreatic carcinoma.
Methods Sixty advanced pancreatic carcinoma patients between January 2009 and May 2013 were randomly assigned into the experimental group (n=30, Jinlong capsule combined with transarterial chemoembolization) and the control group (n=30, transarterial chemoembolization). Both groups were subjected to superselective pancreas artery chemotherapy with GEMZAR at a dose of 1.0 g/m2.
Results The overall response rate (CR+PR) was 53.3% and the control rate was 70% (CR+PR+SD) (CR 0, PR 16, SD 5) in the experimental group, whereas those in the control group were 36.7% and 56.7% (CR 0, PR 11, SD 6), respectively. The short-term therapeutic efficacy was higher in the experimental group than in the control group (P < 0.05). No significant difference in adverse reactions, including digestive reactions and myelosuppression, almost I-II degree, was observed between the two groups (P>0.05). No significant difference in the Karnofsky performance status was observed between the two groups after the treatment (P < 0.05). The 24-month survival rate of the experimental group was 50.0%, whereas that of the control group was 33.3% (P < 0.05).
Conclusion The application of Jinlong capsule combined with transarterial chemoembolization for the treatment of advanced pancreatic carcinoma showed good clinical effects. The patients also showed good tolerance to this treatment.